Navigation Links
Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
Date:12/28/2009

linical and clinical trials of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec® for gastrointestinal GVHD include the risks that: the FDA's requirement that Soligenix conduct additional clinical trials to demonstrate the safety and efficacy of orBec® will take a significant amount of time and money to complete and positive results leading to regulatory approval cannot be assumed; Soligenix is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marketing, sales and distribution of its products; orBec® may not gain market acceptance if it is eventually approved by the FDA; and others may develop technologies or products superior to orBec®. Factors affecting the development and use of SGX201 and LPM((TM)) are similar to those affecting orBec®. These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K. Unless required by law, Sol
'/>"/>
SOURCE Soligenix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
2. Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 /PRNewswire-iReach/ -- ChemImage announced today ... improvements in the development of imaging technology ... normal and diseased tissue that minimizes the ... procedures, lowers surgical costs and potentially enhances ... The clinical and scientific teams ...
(Date:9/17/2014)... 17, 2014 Prostate Oncology Specialists announces ... to educate men about new imaging technology destined ... prostate. Annually, a million men undergo random needle ... MRI (MP-MRI) of the prostate gland is non-invasive ... need to be fully informed of their alternatives. ...
(Date:9/17/2014)... , Sept. 17, 2014  Rebiotix Inc. announced this morning ... lead product candidate, RBX2660 (microbiota suspension) will be presented in ... conference in Philadelphia from October 8-12. ... during the poster session on Thursday, October 9, 2014: ... Infection: 60-Day Interim Analysis of the PUNCH-CD Phase 2 ...
Breaking Medicine Technology:Patient Outcomes Improve When Molecular Chemical Imaging Technology Is Used to Aid Robotic Surgical Procedures, According to New White Paper 2Prostate Cancer Awareness Month - Stop Random Biopsies 2Prostate Cancer Awareness Month - Stop Random Biopsies 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 4
... ... ... ... ...
... , ... ... ... ...
Cached Medicine Technology:American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA 2American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA 3American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA 4American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA 5American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA 6American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA 7Dialysis Corporation of America Announces Fiscal Year 2009 Earnings Release Date 2Dialysis Corporation of America Announces Fiscal Year 2009 Earnings Release Date 3Dialysis Corporation of America Announces Fiscal Year 2009 Earnings Release Date 4
(Date:9/17/2014)... The Food and Drug Administration (FDA) has scheduled ... , 1. The appropriate indicated population ... 2. The potential for adverse cardiovascular outcomes associated with ... an informally-organized litigation group subcommittee prepared a presentation for ... Among others, ZKB attorney Michelle L. Kranz and ZKB ...
(Date:9/17/2014)... September 17, 2014 Why are Asian Americans ... Caucasian Americans, and prone to develop the disease at ... lie in the transition from traditional high-fiber, low-fat Asian ... risks for those of Asian heritage, says George King, ... Joslin Diabetes Center and the senior author of the ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 A petition ... ) in laparoscopic hysterectomies and other gynecological surgeries has ... to figures posted on Change.org, at least 84,908 supporters ... , According to a recent report from ABC News, ... by Dr. Hooman Noorchashm, after his wife, Dr. Amy ...
(Date:9/17/2014)... Cadiz Laser Spa offers the latest, most effective ... Central Texas. The newest addition to their impressive ... the revolutionary Rejuvapen micro-needling device Cadiz Laser Spa ... wide variety of skin issues. , The treatment ... is currently offering a special package through September ...
(Date:9/17/2014)... The Delta Dental Community Care Foundation announced ... Oral Health Foundation: America‚Äôs ToothFairy (NCOHF) to support oral ... Health Zone Program® in California. , The Orange County ... of local constituent groups and stakeholders in a comprehensive ... and its devastating effects on local families. The support ...
Breaking Medicine News(10 mins):Health News:FDA Advisory Committee Holds Hearing on Testosterone Safety 2Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 2Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 3Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 4Health News:Revolutionary Collagen Induction Therapy is Now Available at Cadiz Laser Spa 2Health News:Delta Dental Community Care Foundation Donation to America's ToothFairy Helps Deliver Critical Services 2
... Dr. ... ... Marc Sedwitz, MD, as the new chief of staff of the 372-bed facility. Dr. Sedwitz will ... , ,During his two-year term, Dr. Sedwitz will serve as medical staff liaison to Scripps La ...
... , , SANTA ANA, Calif., Dec. 14 Grubb ... of directors has authorized a daily distribution to stockholders of record ... period commencing on Jan. 1, 2010 and ending on Feb. 28, ... in the calendar year and will be equal to an annualized ...
... to scans performed in 2007 , MONDAY, Dec. 14 ... to far more radiation than previously thought and in doses ... two new studies claim. , Based on the findings, reported ... Internal Medicine , the study authors, joined by Archives ...
... are underdiagnosed, poorly treated and highly stigmatized, according to ... M.D., Ph.D. So these Washington University physicians have written ... Psychiatry," Zorumski and Rubin, who have more than 50 ... families, say some of the problems related to psychiatric ...
... ... tipped off a promotion--Send a Net. Save a Life. See a Game. presented by HP--to ... the NBA Cares Season of Giving and runs through January 31, 2010. ... New York, NY (Vocus) December ...
... , , ... year-old mother from Phoenix who lost 120 pounds (half her size) in ... weight-loss program and foods, appeared this morning on the Joy Fit Club ... nutritionist and author Joy Bauer, airs twice a month and salutes those ...
Cached Medicine News:Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 2Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 3Health News:Grubb & Ellis Healthcare REIT II Declares Initial Distribution 2Health News:Grubb & Ellis Healthcare REIT II Declares Initial Distribution 3Health News:Studies Quantify Cancer Risks From CT Scans 2Health News:Studies Quantify Cancer Risks From CT Scans 3Health News:Studies Quantify Cancer Risks From CT Scans 4Health News:Book demystifies psychiatry for the general public 2Health News:Book demystifies psychiatry for the general public 3Health News:NBA Cares and United Nations Foundation Partner to Launch Send A Net. Save A Life. See A Game. Presented By HP 2Health News:NBA Cares and United Nations Foundation Partner to Launch Send A Net. Save A Life. See A Game. Presented By HP 3Health News:NBA Cares and United Nations Foundation Partner to Launch Send A Net. Save A Life. See A Game. Presented By HP 4Health News:Size 24 to 6 in Just 6 Months: NBC's Today Show Celebrates Dr. Siegal's Cookie Diet Success Story on Joy Fit Club 2Health News:Size 24 to 6 in Just 6 Months: NBC's Today Show Celebrates Dr. Siegal's Cookie Diet Success Story on Joy Fit Club 3Health News:Size 24 to 6 in Just 6 Months: NBC's Today Show Celebrates Dr. Siegal's Cookie Diet Success Story on Joy Fit Club 4
AST (SGOT) reagent is used for the quantitative determination of aspartate aminotransferase (AST) in human serum....
Intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma. Reaction: Kinetic. Wavelength: 340 nm. Linearity: 440 U/L at 30C. Single vial, dry powder reagen...
... stainer TST 44 is an "assembly-line worker" ... histology and cytology laboratories. It automatically stains ... Its again increased large number of reagent ... principle provides a high throughput. Up to ...
HMS 760 Robot Stainer. Version includes display....
Medicine Products: